Insider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 3,273 Shares of Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Sophia Randolph sold 3,273 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $5.82, for a total transaction of $19,048.86. Following the completion of the transaction, the insider now directly owns 327,076 shares of the company’s stock, valued at approximately $1,903,582.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sophia Randolph also recently made the following trade(s):

• On Monday, May 13th, Sophia Randolph sold 12,000 shares of ALX Oncology stock. The stock was sold at an average price of $15.94, for a total transaction of $191,280.00.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO traded down $0.12 during mid-day trading on Wednesday, reaching $5.60. 451,665 shares of the company’s stock were exchanged, compared to its average volume of 586,451. ALX Oncology Holdings Inc. has a twelve month low of $3.94 and a twelve month high of $17.83. The business’s fifty day moving average price is $11.66 and its 200-day moving average price is $13.13. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.21 and a quick ratio of 5.21.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.16. As a group, equities research analysts forecast that ALX Oncology Holdings Inc. will post -2.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Monday, June 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Wednesday, May 29th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.67.

Institutional Investors Weigh In On ALX Oncology

A number of hedge funds have recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co acquired a new stake in ALX Oncology in the first quarter worth $27,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in ALX Oncology during the 4th quarter valued at $28,000. EntryPoint Capital LLC bought a new stake in ALX Oncology during the 1st quarter valued at $32,000. China Universal Asset Management Co. Ltd. raised its holdings in ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after buying an additional 4,706 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of ALX Oncology in the third quarter valued at $168,000. 97.97% of the stock is currently owned by institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.